Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 28.97 USD 0.42% Market Closed
Market Cap: 4.8B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ALKS stock under the Base Case scenario is 28.2 USD. Compared to the current market price of 28.97 USD, Alkermes Plc is Overvalued by 3%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALKS Relative Value
Base Case
28.2 USD
Overvaluation 3%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.2
P/S
P/S
Price to Sales
3.2
vs History
55
vs Industry
68
Median 3Y
3.2
Median 5Y
3.3
Industry
7.7
Forward
3.4
More Details
13.7
P/E
P/E
Price to Earnings
13.7
vs History
28
vs Industry
9
Median 3Y
13
Median 5Y
-27.6
Industry
24.4
Forward
16.1
More Details
9.2
P/OCF
P/OCF
Price to OCF
9.2
vs History
88
vs Industry
12
Median 3Y
12.6
Median 5Y
27.2
Industry
21.1
More Details
10
P/FCFE
P/FCFE
Price to FCFE
10
vs History
77
vs Industry
3
Median 3Y
14.4
Median 5Y
16.3
Industry
22.9
More Details
2.9
P/B
P/B
Price to Book Value
2.9
vs History
85
vs Industry
25
Median 3Y
3.7
Median 5Y
3.6
Industry
3
More Details
2.5
EV/S
EV/S
Enterprise Value to Sales
2.5
vs History
73
vs Industry
61
Median 3Y
2.8
Median 5Y
2.8
Industry
8.2
Forward
2.7
More Details
2.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.9
vs History
74
vs Industry
62
Median 3Y
3.3
Median 5Y
3.4
Industry
10.5
More Details
9.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
9.3
vs History
44
vs Industry
11
Median 3Y
8.6
Median 5Y
8.6
Industry
5.5
Forward
10.5
More Details
10.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
10.1
vs History
22
vs Industry
10
Median 3Y
9.2
Median 5Y
-24.9
Industry
5.7
Forward
17
More Details
7.2
EV/OCF
EV/OCF
Enterprise Value to OCF
7.2
vs History
92
vs Industry
13
Median 3Y
10.5
Median 5Y
25.8
Industry
6.2
More Details
7.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
7.9
vs History
77
vs Industry
9
Median 3Y
10.8
Median 5Y
12.8
Industry
4.3
More Details
3.3
EV/IC
EV/IC
Enterprise Value to IC
3.3
vs History
33
vs Industry
34
Median 3Y
3.3
Median 5Y
3.1
Industry
5.3
More Details

Multiples Across Competitors

ALKS Competitors Multiples
Alkermes Plc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Alkermes Plc
NASDAQ:ALKS
4.8B USD 3.2 13.7 9.3 10.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 051 945.7 -161 843.8 -196 530.1 -194 287.4
US
Abbvie Inc
NYSE:ABBV
369.5B USD 6.3 99.2 16.3 23.7
US
Amgen Inc
NASDAQ:AMGN
159.5B USD 4.6 24.1 18.8 18.8
US
Gilead Sciences Inc
NASDAQ:GILD
147.5B USD 5.1 23.4 10.8 14.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 068.9 -527.9 -574.9 -559.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.1B USD 8.9 27.8 20.5 21.4
AU
CSL Ltd
ASX:CSL
109.4B AUD 4.5 23.5 15.4 19.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
62.9B USD 4.4 14.1 12.7 14.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
60B USD 24.4 -188.1 -470.5 -323
US
Seagen Inc
F:SGT
39.3B EUR 19.9 -61.1 -65.9 -59.4
P/S Multiple
Revenue Growth P/S to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average P/S: 3 095 826.9
3.2
-2%
N/A
FR
Pharnext SCA
OTC:PNEXF
34 051 945.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.3
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
E
Epizyme Inc
F:EPE
2 068.9
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
8.9
10%
0.9
AU
CSL Ltd
ASX:CSL
4.5
8%
0.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.4
4%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
24.4
31%
0.8
US
S
Seagen Inc
F:SGT
19.9
30%
0.7
P/E Multiple
Earnings Growth PEG
IE
Alkermes Plc
NASDAQ:ALKS
Average P/E: 32.3
13.7
-12%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 843.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
99.2
88%
1.1
US
Amgen Inc
NASDAQ:AMGN
24.1
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
23.4
189%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.9 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.8
N/A N/A
AU
CSL Ltd
ASX:CSL
23.5
15%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.1
7%
2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -188.1 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average EV/EBITDA: 14.8
9.3
-7%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 530.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.8
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.8
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.9 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.5
17%
1.2
AU
CSL Ltd
ASX:CSL
15.4
12%
1.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
9%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -470.5 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average EV/EBIT: 17.5
10.1
-27%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 287.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.8
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.9
12%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.5 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.4
17%
1.3
AU
CSL Ltd
ASX:CSL
19.2
16%
1.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.3
10%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -323 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A N/A

See Also

Summary
ALKS intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALKS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALKS stock valuation using valuation multiples.
Wall Street Estimates
ALKS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALKS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 276,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.